Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Implementation of DPYD genotyping in fluoropyrimidine-treated Finnish cancer patients
2018-002255-15Phase 4Active
- Sponsor
- Helsinki University Hospital
- Start
- May 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fluorouracil, capecitabine and tegafur in colorectal cancer (CRC) and breast cancer, sponsored by Helsinki University Hospital. Primary endpoint: Plasma and capillary blood concentrations of fluorouracil, tegafur, capecitabine and their metabolites. Started May 2019; status: active.
02
Drugs
fluorouracilcapecitabinetegafur
03
Conditions
colorectal cancer (CRC)breast cancer
Beyond the preview
Go deeper on 2018-002255-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002255-15.